MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.tranon.2026.103042

Медицинская библиотека · Translational oncology · 2026

NAT-A exhibits anti-tumor activity against acquired epidermal growth factor receptor- tyrosine kinase inhibitor-resistant non-small cell lung cancer via inhibiting the β-catenin/PKM2 axis.

Liu Liyun, Wang Xin, Wang Xinkai, Guan Li, Liao Yahui, He Qi, Sun Yanxi, Wu Ying, Lin Xiao, Wang Shuping, Zhou Yongjun, Zhou Guohua, Jiao Weihua, Lin Hou Wen, Sun Fan

СтатьяПеревод в очереди

Аннотация

Hyperactivation of the Wnt/β-catenin pathway is a key driver of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance in non-small cell lung cancer (NSCLC), with pyruvate kinase M2 (PKM2) serving as a critical transcriptional coactivator of β-catenin. We show that PKM2 upregulation is associated with TKI resistance through stabilizing β-catenin and amplifying Wnt/β-catenin signaling, suggesting a non-canonical or catalytic activity-independent role of PKM2. Here, we identify Neoantimycin-A (NAT-A), a natural compound isolated from Streptomyces conglobatus by our group, as a novel therapeutic agent that suppresses EGFR-TKI-resistant NSCLC. Mechanistically, NAT-A disrupts the interaction between phosphorylated PKM2 (Ser37/Y105) and β-catenin, promoting β-catenin degradation in a PKM2-dependent manner and subsequent suppression of downstream oncogenic signaling. Both in vitro and in vivo studies confirm NAT-A's anti-tumor efficacy, including inhibition of cell proliferation and induction of apoptosis in EGFR-TKI-resistant models. Our findings demonstrate that activation of the PKM2/β-catenin axis drives EGFR-TKI resistance, and highlight NAT-A as a candidate agent that interferes with their interaction to exert anti-tumor effects against refractory EGFR-TKI-resistant NSCLC.

Для цитирования: Liu Liyun, Wang Xin, Wang Xinkai, Guan Li, Liao Yahui, He Qi, Sun Yanxi, Wu Ying, Lin Xiao, Wang Shuping, Zhou Yongjun, Zhou Guohua, Jiao Weihua, Lin Hou Wen, Sun Fan. NAT-A exhibits anti-tumor activity against acquired epidermal growth factor receptor- tyrosine kinase inhibitor-resistant non-small cell lung cancer via inhibiting the β-catenin/PKM2 axis.. Translational oncology. 2026. DOI: 10.1016/j.tranon.2026.103042.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.